The respiratory tract is heavily populated with innate immune cells, but the mechanisms that control such cells are poorly defined. Here we found that the E3 ubiquitin ligase TRIM29 was a selective regulator of the activation of alveolar macrophages, the expression of type I interferons and the production of proinflammatory cytokines in the lungs. We found that deletion of TRIM29 enhanced macrophage production of type I interferons and protected mice from infection with influenza virus, while challenge of Trim29 −/− mice with Haemophilus influenzae resulted in lethal lung inflammation due to massive production of proinflammatory cytokines by macrophages. Mechanistically, we demonstrated that TRIM29 inhibited interferon-regulatory factors and signaling via the transcription factor NF-B by degrading the adaptor NEMO and that TRIM29 directly bound NEMO and subsequently induced its ubiquitination and proteolytic degradation. These data identify TRIM29 as a key negative regulator of alveolar macrophages and might have important clinical implications for local immunity and immunopathology.
Acute viral and bacterial infections in the respiratory tract remain major causes of morbidity and mortality, with an estimated 3.5 million annual deaths worldwide 1 . The innate immune system constitutes the first line of host defense against pathogens 2 . Among the innate immune cells, macrophages are essential for host defense in the lungs through their ability to survey the exposed airways and regulate innate and adaptive immune responses 3 . In the lungs, macrophages are the most abundant immune cells under homoeostatic conditions 4 . Alveolar macrophages (AMs) are found in the airspace of the alveoli and form 90-95% of the cellular content within the alveoli under normal conditions, which makes them the natural 'gatekeepers' of the respiratory tract 5, 6 . Indeed, AMs are the main effector cells in innate host defense in the lungs and also have a crucial role in lung development, surfactant homeostasis and immunosurveillance 6, 7 . AMs interact with alveolar epithelial cells, dendritic cells and T cells via a network of cell-surface receptors, chemokines and cytokines to 'fine tune' the immune responses to viral, bacterial and fungal infections in the lungs 6, 7 . They exert these effects via phagocytic activities and the secretion of antimicrobial factors, nitric oxide, tumor-necrosis factor (TNF) and type I and type II interferons 3 . Because of their potent phagocytic ability, AMs are essential in clearance of bacteria and fungi, including Streptococcus pneumonia, Mycobacteria tuberculosis, Pseudomonas aeruginosa and Pneumocystis carinii [8] [9] [10] [11] . Among viral respiratory infections, the best-studied example is infection with influenza virus, which is the leading cause of death from infection worldwide 12 . Some evidence suggests that AMs are critical for protection from respiratory failure and associated morbidity after infection with influenza virus. In animal models, a lack of AMs in mice leads to impaired clearance of virus and increased mortality in response to infection with low doses of influenza virus [13] [14] [15] [16] , while overexpression of the cytokine GM-CSF prevents AM apoptosis and provides resistance to a lethal dose of influenza virus 14 . AMs are less-efficient producers of infectious viral particles than are alveolar epithelial cells 15 , but they potently upregulate the production of type I interferons 13, 16 and thereby interfere with viral spreading 17 . This ameliorates morbidity through the induction of interferon-inducible antiviral proteins 18, 19 , which inhibit the recruitment of neutrophils as well as the production of proinflammatory cytokines 17 . Although activation of AMs is critical for killing pathogens, this activation must be tightly regulated for the host to effectively control and eliminate invading microorganisms while limiting unwanted tissue damages. Inappropriate activation and excessive production of cytokines have been linked to severe immunological disorders, such as systemic lupus erythematosus 20 , asthma 21 , tissue inflammation and lung damage 22 . Much effort has been devoted to the development of strategies to control excessive activation of the immune system and tissue damage 23 . Among those, the ubiquitination and degradation of critical signaling molecules have emerged as a pivotal mechanism in the control of innate immunity 24 . Here we report that AMs specifically expressed the E3 ubiquitin ligase TRIM29, a member of the 'tripartite interaction motif ' (TRIM) family, and that TRIM29 had a crucial role in the regulation of macrophage activation in response to viral and bacterial infections in the respiratory tract.
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VOLUME 17 NUMBER 12 DECEMBER 2016 nature immunology A r t i c l e s RESULTS TRIM29 inhibits cytokine production in AMs Because of the importance of AMs and the role of ubiquitination in regulating innate immune cells, we screened all 70 members of the TRIM family of E3 ubiquitin ligases in the mouse AM cell line MH-S by a small-interfering-RNA approach. We found that knocking down TRIM29 in MH-S cells led to markedly enhanced (over threefold) production of interferon-β (IFN-β) in response to 5′-triphosphorylated RNA (5′pppRNA), the ligand of RIG-I-like receptors (RLRs)), when delivered via Lipofectamine (data not shown). We confirmed those results by stable knockdown of TRIM29 via short hairpin RNA (shRNA) in this cell line and found that two distinct TRIM29-targeting shRNAs produced efficient knockdown of TRIM29 (Fig. 1a) . We then stimulated these cells with 5′pppRNA and measured the production of IFN-β and the cytokine IL-6 by the stimulated cells by ELISA. Consistent with published data [25] [26] [27] , knockdown of the signaling adaptor MAVS via shRNA abrogated the production of both IFN-β and IL-6 in macrophages stimulated by cytosolic 5′pppRNA (Fig. 1b,c) . In contrast, knockdown of TRIM29 markedly enhanced the production of IFN-β and IL-6 by macrophages by up to fourfold relative to their production by cells treated with control (nontargeting) shRNA (Fig. 1b,c) . These data suggested that TRIM29 negatively regulated the production of IFN-β and IL-6 in AMs in response to 5′pppRNA.
Sensing of 5′pppRNA, poly(I:C) and RNA viruses by TRIM29 To determine the role of TRIM29 in primary cells, we first analyzed the expression of TRIM29 in primary mouse cells by real-time PCR. We found high expression of TRIM29 in AMs but not in other cell types (Fig. 1d) . To further determine the function of TRIM29 in innate immunity, we obtained TRIM29-deficient (Trim29 −/− ) mice and confirmed loss of TRIM29 in these mice by PCR genotyping and immunoblot analysis ( Supplementary Fig. 1a,b) . We first isolated primary AMs from wild-type and Trim29 −/− mice, then stimulated the cells with 5′pppRNA and the highmolecular-weight synthetic RNA duplex poly(I:C) (poly(I:C) (HMW), the ligand for the RNA helicase and cytosolic receptor MDA5. ELISA showed that Trim29 −/− AMs produced three-to fivefold more type I interferons (IFN-α and IFN-β) and proinflammatory cytokines (TNF and IL-6) than wild-type AMs did in response to 5′pppRNA or poly(I:C) at 6 h (Fig. 2a) or 12 h (Fig. 2b,c) after stimulation, indicative of a negative role for TRIM29 in AMs in response to ligands of RLRs.
Infection with influenza virus produces typical 5′pppRNA and/or double-stranded RNA, while infection with reovirus produces mainly double-stranded RNA 28 . We therefore used influenza A virus (PR8 strain) and reovirus (type 3, Dearing strain) to investigate the role of TRIM29 in AMs. We isolated AMs from wild-type and Trim29 −/− mice and infected the cells with influenza virus or reovirus. Trim29-deficient AMs produced three-to sevenfold more type I interferons and proinflammatory cytokines at 6 h (Fig. 2a) or 12h (Fig. 2b,c) after infection than did wild-type cells. Similar results were obtained at 20 h after infection by influenza virus (Supplementary Fig. 2a-d) . The primary AMs from wild-type and Trim29 −/− mice were similar in term of the expression of differentiation markers ( Supplementary  Fig. 2e ). To determine whether TRIM29 has a role in regulating other cytokines and chemokines, we isolated primary AMs from wild-type and Trim29 −/− mice and stimulated the cells with 5′pppRNA or influenza virus. Trim29-deficient AMs produced two-to fivefold more chemokines, including MIP-1α (Supplementary Fig. 3a) , CCL-2, CCL-5 and CXCL-2 ( Supplementary Fig. 3b) , than did wild-type cells. In contrast, knockout of TRIM29 had no effect on the production of IL-10 ( Supplementary Fig. 3c ), IL-4, IL-5 or IL-13 ( Supplementary Fig. 3d ). To determine whether TRIM29 negatively regulates cytokine production in other cell types, we isolated peritoneal macrophages, splenic macrophages and CD11c + splenic dendritic cells from wild-type mice and Trim29 −/− mice and stimulated the cells with 5′pppRNA or influenza virus. We found that TRIM29 deficiency had no effect on IL-6 production in response to 5′pppRNA in peritoneal macrophages (Supplementary Fig. 4a ) or in splenic macrophages (Supplementary Fig. 4b ). In contrast, TRIM29-deficient CD11c + splenic dendritic cells produced twofold more type I interferons and proinflammatory cytokines in response to 5′pppRNA or infection with influenza virus than did wild-type cells ( Supplementary Fig. 5a-d) , which suggested an inhibitory role for TRIM29 in CD11c + splenic dendritic cells in response to 5′pppRNA or an RNA virus. Together these data demonstrated a negative role for TRIM29 in primary AMs in response to not only the intracellular RLR ligands 5′pppRNA and poly(I:C) but also RNA viruses.
TRIM29 modulates responses against RNA viruses
We next evaluated the importance of TRIM29 in vivo in mediating host defense against viral infection. We first infected wild-type and Trim29 −/− mice intranasally with influenza virus, which is transmitted by an oral or nasal route in nature, and monitored both survival and body-weight changes over time. The wild-type mice were all dead between day 6 and day 9 after infection with high dose of virus (1 × 10 5 plaque-forming units (PFU) per mouse). In contrast, none of the Trim29 −/− mice succumbed to this infection (Fig. 3a) . In addition, the Trim29 −/− mice started to regain body weight at 4 or 5 d after infection with a high dose of virus, while the wild-type mice continued to lose body weight until death (Fig. 3b) . When infected with a low dose of influenza virus (1 × 10 2 PFU per mouse), both wild-type mice and Trim29 −/− mice survived, but the difference in body-weight changes was striking: wild-type mice continued to lose body weight until day 9 after infection, while Trim29 −/− mice gained body weight during this time period (Fig. 3c) . In addition, Trim29 −/− mice had three-to fivefold more type I interferons in bronchoalveolar lavage fluid (BALF) than did wild-type mice at day 2 or day 4 after infection with either a high dose or a low dose (Fig. 3d,e) . Also, there was twoto threefold more IL-6 in BALF from Trim29 −/− mice than in that from wild-type mice at day 2 or day 4 after infection ( Supplementary  Fig. 5e ,f). We also measured titers of influenza virus in lung homogenates by plaque-forming assay after infection and found that the viral load was minimal in Trim29 −/− mice, in contrast to that in wild-type mice (1 × 10 2 PFU (Trim29 −/− ) versus 1 × 10 7 PFU (wild-type) at day 4 after infection with 1 × 10 5 PFU per mouse infection, and 9 PFU (Trim29 −/− ) versus 1 × 10 3 PFU (wild-type) at day 4 after infection with 1 × 10 2 PFU per mouse; Fig. 3f,g ). Furthermore, histopathology revealed that the edema, alveolar hemorrhaging, alveolar wall thickness and neutrophil infiltration in Trim29 −/− lungs was much lower than that of wild-type lungs after viral infection (Fig. 3h) . These data indicated that TRIM29 inhibited activation of the innate immune system, especially the production of type I interferons by AMs, and thus allowed the virus to escape attack by the host immune system 29 .
Role of TRIM29 in bacteria-induced acute lung inflammation As TRIM29 has high expression specifically in lung primary AMs, we reasoned that the TRIM29 might also protect lungs from injury by acute bacterial infection. Lipopolysaccharide (LPS) is the main component of the outer membrane of Gram-negative bacteria and often induces strong immune responses in animals. We therefore stimulated wild-type and TRIM29-deficent primary AMs with LPS and compared their production of proinflammatory cytokines. Notably, challenge of wild-type AMs with LPS induced tenfold greater production of TNF and IL-6 than that of unstimulated wild-type AMs but induced minimal production of type I interferon ( Fig. 4a and Supplementary  Fig. 6a ). TRIM29-deficient AMs produced up to sevenfold more proinflammatory cytokines than did wild-type cells in response to LPS challenge (Fig. 4a) . We next used an LPS-induced septic-shock model to further investigate the in vivo function of TRIM29 in acute lung inflammation. In this acute model, death occurs within hours, mainly due to the production of TNF 30, 31 . Age-matched wild-type and Trim29 −/− littermates were inoculated intranasally with LPS. LPS caused the death of most Trim29 −/− mice within 24 h (Fig. 4b) .
In contrast, only 25% of wild-type mice showed septic shock within 36 h, a time at which all Trim29 −/− mice were dead (Fig. 4b) .
We then used the respiratory bacteria H. influenzae to further investigate the role of TRIM29 in acute lung inflammation. We delivered H. influenzae intratracheally into wild type and Trim29 −/− mice and monitored the survival of these mice. We found that mortality in Trim29 −/− mice was 80% at 8 d after infection, while the mortality of wild-type mice was only 20% (Fig. 4c) . We also collected BALF from A r t i c l e s LPS-challenged mice or H. influenzae-infected mice and measured the concentrations of proinflammatory cytokines. Consistent with the survival results, concentrations of the proinflammatory cytokines TNF, IL-6 and IL-1β (Fig. 4d,e) as well as that of MIP-1α ( Supplementary  Fig. 6b ) were more than tenfold higher (LPS) or fourfold higher (H. influenzae) in Trim29 −/− mice than in wild-type mice. The production of type I interferons did not show much difference in wild type mice relative to that in Trim29 −/− mice ( Supplementary  Fig. 6c,d) . These results suggested a critical role for TRIM29 in limiting LPS-or H. influenza-induced acute lung injury.
TRIM29 induces NEMO degradation in AMs
To investigate the mechanisms by which the enhanced production of type I interferons and expression inflammatory cytokines were achieved in AMs in Trim29 −/− mice, we isolated AMs from wildtype and Trim29 −/− mice and infected the cells with influenza virus or treated them with LPS for various times, then assessed activation of the transcription factors IRF3 and NF-κB by immunoblot analysis. We found that phosphorylation of IRF3 and the NF-κB subunit p65 in TRIM29-deficient AMs was enhanced relative to that in wildtype AMs after viral infection (Fig. 5a) . Additionally, treatment with LPS induced rapid and robust upregulation of the expression and phosphorylation of p65, but not the phosphorylation of IRF3, in TRIM29-deficient AMs relative to that in wild-type AMs (Fig. 5b) . To further investigate how TRIM29 regulates such signaling molecules, we used immunoprecipitation with an antibody specific to TRIM29 to identify TRIM29-interacting proteins in lysates of AMs, followed by protein sequencing by liquid chromatography-mass spectrometry. Among a group of TRIM29-interacting proteins, we identified NEMO, the regulatory subunit of the NF-κB complex (Supplementary Table 1 ). Because TRIM29 is expressed specifically in resting AMs, we isolated both primary AMs and peritoneal macrophages to measure endogenous TRIM29 and NEMO. The abundance of TRIM29 was much greater in wild-type AMs than in peritoneal macrophages; in contrast, the abundance of NEMO was much lower in AMs than in peritoneal macrophages (Fig. 5c) . Notably, the amount of NEMO in AMs and peritoneal macrophages from Trim29 −/− mice was similar to that in their counterparts from wild-type mice (Fig. 5c) . These data indicated that TRIM29 expression in AMs might limit NEMO expression. To investigate that possibility, we isolated macrophages and bone-marrow-derived dendritic cells from wildtype mice and treated them for 6 h with LPS, IFN-α or infection with reovirus. We found that TRIM29 expression was induced in dendritic cells by infection with reovirus but not by treatment with LPS or IFN-α (Fig. 5d) and could not be further induced in macrophages (Supplementary Fig. 7 ). The amount of NEMO was much lower in bone-marrow-derived dendritic cells infected with reovirus than those treated with LPS or IFN-α (Fig. 5d) . AMs have high expression of TRIM29, and GM-CSF is known to be a critical regulator of protein expression in the airspaces 1 . We next determined whether GM-CSF was able induce TRIM29 expression in macrophages. TRIM29 expression was substantially induced in peritoneal macrophages by treatment with GM-CSF but was marginally induced in bone-marrow-derived macrophages by GM-CSF (Fig. 5e) . Because TRIM29 is an E3 ubiquitin ligase, we next determined whether NEMO is the target of TRIM29 for ubiquitination and degradation. Coexpression of NEMO with TRIM29 showed that TRIM29 induced complete degradation of NEMO, and treatment with the proteasome inhibitor MG132 rescued it from this degradation ( Fig. 5f) , which suggested that TRIM29 was able to induce proteasome-dependent degradation of NEMO. Together these data indicated that TRIM29 inhibited the activation of IRF3 and p65 in AMs by degrading NEMO in response to viral infection or LPS treatment.
TRIM29 binds to and colocalizes with NEMO in lysosome
To ascertain the physical interactions between TRIM29 and NEMO, we investigated the interactions between Myc-tagged recombinant NEMO and hemagglutinin (HA)-tagged full-length TRIM29, as well as truncation mutants of TRIM29 (Supplementary Fig. 8a ). Both full-length TRIM29 and the OmpH ('outer membrane protein H') domain of TRIM29 bound NEMO (Fig. 6a) . Additionally, the mapping results for Myc-tagged recombinant TRIM29 and HA-tagged full-length NEMO and their truncation mutants ( Supplementary  Fig. 8b) showed that the OmpH domain of NEMO bound TRIM29 (Fig. 6b) ; this suggested that the interaction between TRIM29 and NEMO was mediated by the OmpH-OmpH domains. Next, we expressed Myc-tagged NEMO together with HA-tagged fulllength TRIM29 or mutant TRIM29 lacking the NEMO-binding site (TRIM29 BBOX) in human embryonic kidney cells (HEK293T cells) to determine their subcellular localization. Immunofluorescence analysis showed that full-length TRIM29 colocalized with NEMO in the cytosol (Fig. 6c) . In contrast, TRIM29 BBOX did not colocalize with NEMO (Supplementary Fig. 8c) . Furthermore, subcellular colocalization analysis showed that TRIM29 colocalized with the lysosome marker LAMP1 (Fig. 6c) but not with a mitochondrial marker, the endosomal marker TfR or the autophagosome marker LC3A (Supplementary Fig. 8d) . Additionally, viral infection had no effect on the colocalization of TRIM29 with LAMP1 ( Supplementary  Fig. 8e ). These data suggested that TRIM29 bound to NEMO via the OmpH-OmpH domains and that it colocalized with NEMO in the cytosolic lysosome.
TRIM29 induces NEMO ubiquitination through K48 linkage
To investigate whether NEMO undergoes ubiquitination and whether such ubiquitination of NEMO is dependent on the binding site at which TRIM29 interacts with NEMO, we transfected HEK293T cells with plasmids expressing Myc-tagged NEMO and HA-tagged fulllength TRIM29, the mutant TRIM29 BBOX or full-length ubiquitin ligase TRAF6 to detect the ubiquitination of NEMO. Immunoblot analysis demonstrated that the ubiquitination of NEMO was substantially enhanced by overexpression of TRIM29 but not by the mutant TRIM29 BBOX (Fig. 7a) . Immunoblot analysis of Lys48 (K48)-linked or K63-linked ubiquitination further demonstrated that TRIM29 induced the ubiquitination of NEMO by K48-mediated linkage (Fig. 7a) , while TRAF6, but not TRIM29, induced the ubiquitination of NEMO by K63-mediated linkage (Fig. 7a) .
To determine whether TRIM29 is able to directly modify NEMO, we reconstituted the NEMO-ubiquitination reaction in vitro. 
A r t i c l e s
We analyzed various combinations of recombinant glutathione S-transferase (GST)-tagged NEMO, recombinant TRIM29 or recombinant TRAF6, purified E2 enzymes (HbcH2, HbcH3, HbcH5a, HbcH5b, HbcH5c, HbcH6, HbcH7, HbcH8, HbcH10 and HbcH13) and a mixture of E1 plus ubiquitin plus ATP, followed by precipitation with GST beads and immunoblot analysis. We observed that K48-linked ubiquitination of NEMO (but not its K63-linked ubiquitination) was induced by TRIM29 plus one of the following E2 enzymes: HbcH3, HbcH6 or HbcH10 (Fig. 7b) . In a control assay, the ubiquitination of NEMO by TRAF6 was mediated by K63 linkage (Fig. 7b) . These data indicated that TRIM29 induced the ubiquitination and degradation of NEMO by K48-mediated linkage.
TRIM29 induces NEMO ubiquitination at its Lys183 site NEMO contains 30 lysine residues, and 22 of these were predicted to be possible ubiquitination sites (Supplementary Table 2 ). We therefore replaced each of these lysine residues individually with arginine and found that substitution of Lys161 or Lys183 resulted in partial resistance or complete resistance, respectively, to the ubiquitination and degradation induced by TRIM29 (Fig. 8a) . All other substitutions had no effect on the degradation of NEMO by TRIM29 (data not shown). We next assessed the interaction between the substitution mutants of NEMO and TRIM29 by co-immunoprecipitation assay. Although NEMO with substitution of Lys183 was still able to bind TRIM29, NEMO with substitution of Lys161 lost most of its binding ability (Fig. 8b) . These data suggested that Lys183 is the key ubiquitination site in NEMO. To determine the functional importance of NEMO Lys183, we performed a luciferase reporter assay. Overexpression of TRIM29 inhibited only activation of the promoters of the genes encoding IFN-β or NF-κB induced by wild-type NEMO, not that induced by NEMO with substitution of Lys183 (Fig. 8c,d ). These data indicated that Lys183 was a critical site for TRIM29-mediated ubiquitination and regulation of NEMO.
DISCUSSION
AMs are a major producer of type I interferons and proinflammatory cytokines during respiratory infection, and this effect is initiated by innate sensors and is mediated by several key signaling pathways. Such a response has a key role in local protective immunity as well as in immune-system-mediated pathology 32 . Studies have shown that many inflammation-associated diseases, including some types of cancers, result from dysregulated innate immunity 33 . Therefore, understanding of the molecular mechanisms by which innate immunity is dynamically controlled is critical for the development of novel and more-effective treatments for these diseases 34 . However, the mechanisms that control local innate immunity in the respiratory tract are poorly understood. In this study, we discovered that AMs specifically expressed the E3 ubiquitin ligase TRIM29 and that TRIM29 served a crucial role in the maintenance of immunological homeostasis in the lungs by regulating the stability of NEMO, a key adaptor in both the IRF-mediated type-I-interferon-production pathway and the NF-κB-mediated proinflammatory signaling pathway. We showed that TRIM29 interacted with NEMO via the OmpH-OmpH domains of NEMO and induced the ubiquitination and degradation of NEMO at Lys183 by K48 linkage. Our data suggest that under homeostatic conditions, TRIM29 expression in AMs limits the abundance of NEMO, so the production of proinflammatory cytokines is inhibited and unwanted lung inflammation is suppressed in response to bacterial infection. However, during viral infection, high levels of TRIM29 also interfere with the production of type I interferons, which hinders the generation of anti-viral immunity and thus renders the mice susceptible to virus-induced death. Indeed, we observed that Trim29 −/− mice exhibited significantly reduced morbidity, mortality, lung injury and local inflammation after challenge with influenza virus. On the other hand, Trim29 −/− mice were more susceptible and died of uncontrolled inflammation after challenge with LPS or H. influenzae. Clearly, both models highlight the importance of TRIM29 in regulating innate immunity in the lungs.
The innate immune cells sense pathogen-associated molecular patterns such as viral 5′pppRNA and bacterial LPS to produce type I interferons and proinflammatory cytokines. This response is critical in the defense against viral or bacterial infection. Central to the early host defense against viral infection is the production of type I interferons and the synthesis of antiviral interferon-stimulated gene products contain viral dissemination and activate the adaptive immune response 35, 36 . After infection with an RNA virus, the rapid induction of type I interferons and proinflammatory cytokines is regulated by extracellular and intracellular signals to activate both NF-κB and IRFs 37, 38 . The activation of NF-κB is regulated by the inhibitor-of-NF-κB kinase (IKK) complex composed of IKK-α, IKK-β and NEMO. In parallel, the activation of IRF3 and IRF7 is regulated by the IKK-related kinases TBK1 and IKKε 39, 40 . Further studies have demonstrated that NEMO is also essential for virus-induced activation of IRF3 and IRF7 by recruiting TBK1 and IKKε to the RLR-MAVS complex 41 , which suggests that NEMO is a critical adaptor in both NF-κB signaling and IRF signaling. Published evidence indicates that TRIM29 might have an important role in DNA repair 42 and oncogenesis 43 , which suggests that TRIM29 might have additional functions beyond the regulation of innate immunity. Structurally, TRIM29 belongs to the large TRIM family of E3 ubiquitin ligases, but it lacks a typical RING domain. Instead, TRIM29 has a B-box domain that also has E3 ligase activity. It has been shown that both the RING domain and the B-box domain of TRIM18 have E3 ligase activity, although the B-box domain exhibits weaker E3 ligase activity than that of a typical RING domain 29 . Furthermore, the E3 ligase Peli1 does not contain a typical RING domain, which suggests that not all E3 ligases use a typical RING domain to catalyze ubiquitination 30, 31 .
Published studies have demonstrated that post-translational modification of NEMO by ubiquitination has a critical role in regulating its function in the IKK complex. It has been shown that the adaptor Bcl10 induces NEMO K63-linked ubiquitination 44 . Further studies have confirmed that Bcl10 and the adaptor MALT1 form oligomers to induce the oligomerization of TRAF6 for the polyubiquitination of NEMO by the ubiquitin-conjugating enzyme Ubc13 (ref. 45) . Another study has indicated that endogenous NEMO undergoes linear ubiquitination after viral infection 46 . Furthermore, the E3 ubiquitin ligase TRIM23 induces K27-linked ubiquitination of NEMO for positive regulation of TLR3-and RIG-I-MDA5-mediated antiviral responses 47 . However, it is still unknown whether NEMO undergoes ubiquitination for degradation and thereby negatively regulates the immune responses. Here we have demonstrated that TRIM29 induced the ubiquitination and subsequent degradation of NEMO by K48 linkage to negatively regulate the production of type I interferons as well as proinflammatory cytokines in AMs after infection.
A diverse range of molecules have been identified as important regulators in the signaling pathways of both type I interferon production and inflammatory cytokine production. Our current observations based on the study of Trim29 −/− mice have solidified the proposal of a role for TRIM29 as an in vivo checkpoint of type I interferon and inflammatory cytokine responses. We have extended those findings to influenza virus and identified TRIM29 as a negative regulator of the host immune response to pathogens in the respiratory tract. We predict that TRIM29 mutants lacking E3-ubiquitin-ligase activity might serve as biomarkers for the prediction of lung inflammation and susceptibility to influenza virus.
Although the activation of signaling pathways via the sensing of viral nucleic acids in immune cells is critical for the elimination of invading microorganisms 48 , excessive sensing and overwhelming host cytokine production can lead to tissue damage and autoimmune disease. In this context, the identification of TRIM29 as a key negative regulator of the production of type I interferons as well as proinflammatory cytokines in the lungs might have important implications for the understanding of innate immunity, as well as the study of the pathogenesis of autoimmune diseases.
METHODS
Methods and any associated references are available in the online version of the paper. 
